

FORUM ON NEUROSCIENCE AND NERVOUS SYSTEM DISORDERS

Board on Health Sciences Policy

ALZHEIMER'S DIAGNOSTIC CRITERIA VALIDATION: EXPLORATION OF NEXT STEPS

Presented at the Alzheimer's Association International Conference on Alzheimer's Disease 2011 (AAICAD) in Paris, France from July 16-21, 2011

Monday, July 18th, 2011:

10:30 a.m. Session Overview

MARILYN ALBERT

Director Alzheimer's Disease Research Center John Hopkins University

GABRIELLE SILVER

Global Strategic Marketing Leader, Neurology GE Healthcare

10:40 a.m. Updating the Diagnostic Criteria: Two Guidelines

- Review the primary updates to the criteria
- Examine the similarities and differences between the National Institute of Aging/Alzheimer's Association and International Working Group guidelines
- Discuss the role the new criteria will have in a clinical setting

PHILLIP SCHELTENS

Director

Alzheimer Center

Vrije Universiteit Medical Center

11:05 a.m. Validating the New Criteria: Lessons Learned from Cardiovascular disease and cholesterol [30 min with 10 min Q&A]

- Explore challenges and lessons learned in the validation of cholesterol as a biomarker
- Identify lessons learned that could be applied in the validation of AD guidelines

ROBERT MAHLEY

Senior Investigator

Gladstone Institute of Cardiovascular Disease and Neurological Disease University of California, San Francisco

11:45 a.m. Panel Discussion: Identifying Principle Strategies for Validation of New Criteria

- Identify a set of core principles that can be used to validate the newly proposed diagnostic criteria guidelines for symptomatic pre-dementia and dementia AD
- Discuss next steps and strategies for moving forward
 - o Examine the types of studies needed, their design and execution

WILLIAM THIES, Moderator

Chief Medical and Scientific Officer

Alzheimer's Association

MONIQUE BRETELER

Professor

German Center for Neurodegenerative diseases

CHARLES DeCARLI

Director

Alzheimer's Disease Center

University of California, Davis

DAVID BROOKS

Professor, Imperial College

Chief Medical Officer, GE Healthcare

ROBERT MAHLEY

Senior Investigator

Gladstone Institute of Cardiovascular Disease and Neurological Disease

University of California, San Francisco

12:30 p.m. ADJOURN